Xsphera Biosciences envisions a world where failure is no longer the most likely outcome in oncology clinical trials or patient responses to approved therapies. Our ex vivo platform, invented at the Dana-Farber Cancer Institute, is a powerful integration of biology and cloud computing that accelerates drug development and guides precision medicine.
Our proprietary process enables the simultaneous assessment of multiple therapeutics on a single patient-derived tumor specimen. Xsphera uniquely enables the study of single-variable testing, which is critical to understanding the response behavior of the tumor microenvironment and not possible with in vivo studies.
Approval of a single additional cancer therapy can improve
patient outcomes and generate $billions in revenue
But the vast majority
of new oncology drugs entering clinical trials fail to achieve
And only a minority of patients respond to approved immunotherapies from
try-and-see therapy selection.
Lab instrumentation generates vast amounts of data which is stored across multiple siloed systems accessible only to specialists.
Images, transcriptomic signatures, genomic mutations, immune profiles, and cytokine data become disconnected from the sample and patient data.
Ex vivo platform is a novel combination of processes and technology that allows deep exploration of human responses to drug therapies.
Xsphera unlocks the mysteries of drug mechanisms with our cloud software platform that integrates all of the complex multi-omic response data for each patient in a study into a unified, intelligent and accessible interface.
With Xsphera, novel therapeutics move forward into the clinic with confidence.
Mice are poor predictors of human response… making it difficult to identify the most promising drug candidates to advance into limited clinical trials.
Xsphera’s human tissue-based platform assesses responses of multiple drugs on patients’ active tumor microenvironments…helping identify the best candidates.
High quality, live human tissue samples are sourced from our international clinical network. Xsphera then captures the entirety of each patient’s unique tumor microenvironment within multiple channels of microfluidic devices. Each channel is treated to measure response including the stimulation of immune-mediated tumor cell death.
Drug developers are confronted with vast amounts of overwhelming and scattered data as they attempt to extract scientific understanding from study analytics. As a result, unquantifiable volumes of valuable study data sit un-analyzed on hard drives across the pharma industry.
Our cloud-based platform ingests and integrates tissue, patient and results from all lab instrumentation into a single source of unified data. AI-driven algorithms automate deep analysis and put previously unknowable insights within reach.
The Xsphera mission is to build an integrated biology and cloud software platform
that enables understanding of why a patient responds to or resists cancer therapy.
Founded in 2018, based on
Dana-Farber Cancer Institute research
Exclusively licensed Dana-Farber patented technology
Delivered as a lab-in-the-cloud platform for drug development
Delivered as a functional therapeutic selector for precision medicine